Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

In honor of November being Alzheimer’s Awareness month, BioSpace evaluated the current therapies, drugs in the pipeline and disease outlook.

Read More »

Study shows Apple devices in combo with apps could identify dementia

Drugmaker Eli Lilly and Company said early results from a study suggest that Apple Inc. devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer’s disease dementia and those without symptoms.

Read More »

Eisai Starts Phase III Trials for Second Alzheimer’s Drug After First’s Failure

Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.

Read More »

In What Could Be an Alzheimer’s Breakthrough, UCLA Scientists Link Specific Gene Mutations to Dementia

Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.

Read More »

New Report Expresses Optimism Over Current State of Alzheimer’s Drug Development

Noting that from 1998 to 2017 there were about 146 failed shots at developing drugs for Alzheimer’s disease, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report on the state of the industry.

Read More »

Allergan and Sosei Halt Alzheimer’s Study

Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.

Read More »

Roche gets breakthrough status for Alzheimer’s test Elecsys

The U.S. Food and Drug Administration granted Roche an accelerated review for the Swiss drugmaker’s Elecsys product used to diagnose Alzheimer’s disease.

Read More »

Bill Gates backs $30 million push for early Alzheimer’s diagnostics

Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.

Read More »

Biogen, Eisai’s AD succeeds in mid-stage study

Japanese drugmaker Eisai Co. and Biogen Inc. said the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.

Read More »

Dementia venture fund raises $350 million to hunt new drugs

A venture capital fund dedicated to finding new ways to prevent and treat dementia raised $350 million, far exceeding the initial target of $200 million set on its launch in 2015.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom